Nanobiotix S.A. (NBTX)

FR — Healthcare Sector
Peers: TCRX  INAB  PHIO  IMMX  FDMT  PHVS  ALGS  ELEV 

Automate Your Wheel Strategy on NBTX

With Tiblio's Option Bot, you can configure your own wheel strategy including NBTX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol NBTX
  • Rev/Share 0.8956
  • Book/Share -1.3943
  • PB -4.3023
  • Debt/Equity -0.7747
  • CurrentRatio 1.0429
  • ROIC -1.8841

 

  • MktCap 284359226.1615
  • FreeCF/Share -0.0325
  • PFCF -185.7343
  • PE -8.4449
  • Debt/Assets 0.755
  • DivYield 0
  • ROE 0.7653

 

  • Rating C-
  • Score 1
  • Recommendation Strong Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation NBTX Guggenheim -- Buy -- $12 Aug. 28, 2024

News

Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
NBTX
Published: May 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based approaches to expand treatment possibilities for patients with cancer and other major diseases, announced today that Company management will participate in fireside chats at following conference:

Read More
image for news Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
NBTX
Published: April 30, 2025 by: GlobeNewsWire
Sentiment: Neutral

PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the presentation of full results from the completed dose escalation and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study, conducted by The University of Texas MD Anderson Cancer Center, will be presented by principal investigator Dr. Eugene Koay on Sunday, May 4th at …

Read More
image for news Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call

About Nanobiotix S.A. (NBTX)

  • IPO Date 2020-12-11
  • Website https://www.nanobiotix.com
  • Industry Biotechnology
  • CEO Laurent Levy
  • Employees 108
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.